Sort by

Send to

Choose Destination

Search results

Items: 6


Barriers to drug adherence in the treatment of urea cycle disorders: Assessment of patient, caregiver and provider perspectives.

Shchelochkov OA, Dickinson K, Scharschmidt BF, Lee B, Marino M, Le Mons C.

Mol Genet Metab Rep. 2016 Jul 20;8:43-7. doi: 10.1016/j.ymgmr.2016.07.003. eCollection 2016 Sep.


Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod.

Petri MA, Martin RS, Scheinberg MA, Furie RA.

Lupus. 2016 Jun 26. pii: 0961203316654767. [Epub ahead of print]


Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser.

Scheinberg MA, Hislop CM, Martin RS.

Expert Opin Biol Ther. 2016;16(5):723-33. doi: 10.1517/14712598.2016.1169270.


Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials.

Nagamani SC, Diaz GA, Rhead W, Berry SA, Le Mons C, Lichter-Konecki U, Bartley J, Feigenbaum A, Schulze A, Longo N, Berquist W, Gallagher R, Bartholomew D, Harding CO, Korson MS, McCandless SE, Smith W, Vockley J, Kronn D, Zori R, Cederbaum S, Merritt JL 2nd, Wong D, Coakley DF, Scharschmidt BF, Dickinson K, Marino M, Lee BH, Mokhtarani M.

Mol Genet Metab. 2015 Sep-Oct;116(1-2):29-34. doi: 10.1016/j.ymgme.2015.08.002. Epub 2015 Aug 5.


A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.

Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C, Martin RS, Scheinberg MA; PEARL-SC Study.

Ann Rheum Dis. 2015 Sep;74(9):1667-75. doi: 10.1136/annrheumdis-2013-205144. Epub 2014 Apr 19.


Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice.

Fraser H, Hislop C, Christie RM, Rick HL, Reidy CA, Chouinard ML, Eacho PI, Gould KE, Trias J.

J Cardiovasc Pharmacol. 2009 Jan;53(1):60-5. doi: 10.1097/FJC.0b013e318195bfbc.

Items per page

Supplemental Content

Loading ...
Support Center